• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 26, 2018 at 10:02: AM
via Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck and Pfizer to evaluate the combination of its [fam-] trastuzumab deruxtecan (DS-8201) with avelumab and/or an investigational damage response (DDR) inhibitor of Merck, in patients with HER2 expressing or mutated solid tumors.

article source
 

<



Similar threads

cafead
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Replies
0
Views
15
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Navigating the AI &#039;hype cycle&#039;: Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo-Merck&#039;s &#039;guided-missile&#039; cancer drug meets main goal in late-stage trial
Replies
0
Views
9
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo and MSD announce first subject dosing in lung cancer trial
Replies
0
Views
40
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Replies
0
Views
17
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote